Niveditha Nerlakanti

6PUBLICATIONS
23CO-AUTHORS
Molecular targetsSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 23, 2026
Unc-51 like kinase 3 (ULK3) contributes to autophagy and cell survival in multiple myeloma.

|Aug 20, 2025
Unc-51 Like Kinase 3 (ULK3) is essential for autophagy and cell survival in multiple myeloma.

Marilena Tauro, Tao Li, Praneeth R Sudalagunta

|Mar 20, 2024
The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease.

Ryan T Bishop, Anna K Miller, Matthew Froid

|Jun 30, 2020
Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma.

Jeremy J McGuire, Niveditha Nerlakanti, Chen Hao Lo

|Aug 15, 2019
Betaglycan drives the mesenchymal stromal cell osteogenic program and prostate cancer-induced osteogenesis.

Leah M Cook, Jeremy S Frieling, Niveditha Nerlakanti

|Sep 23, 2018
Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer.

Niveditha Nerlakanti, Jiqiang Yao, Duy T Nguyen

Pageof 1

Frequent Collaborators

4 joint publications

Conor Lynch

2 joint publications

John L Cleveland

2 joint publications

Ariosto Siqueira Silva

2 joint publications

Nicholas Lawrence